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the coronary sinus and right atrium when AF is 
detected. However, battery powered implantable units 
have a fi nite life, requiring further surgery to replace 
them. The 20 J of energy required for  successful 
cardioversion, combined with the automation of the 
ICD, can also signifi cantly impact on the quality of 
life for the patient, as about 22% of the shocks deliv-
ered are unnecessary and occur outside of hospital.
Getting to the heart
As a result, two research priorities in AF electrical 
cardioversion treatment are: optimisation of the 
shock waveform, to reduce discomfort and need for 
sedation; and the development of battery-less, semi- 
passive, implantable atrial defi brillators to facilitate 
AF detection/assessment/treatment in a minimal 
critical care setting.
Pursuing both priorities, the team from the Univer-
sity of Ulster, UK, Universidad Simon Bolivar, 
A battery-less, wirelessly-powered implantable 
defi brillator for atrial fi brillation is being developed 
by an international team of researchers in the UK, 
Venezuela and the US. With the ability to sense the 
electrical impedance of heart tissue, it could allow 
electrical treatment of atrial fi brillation to be 
optimised, reducing pain and required sedation.
Hitting reset
Atrial fi brillation (AF), a disturbance of cardiac 
rhythm that reduces the heart’s output and is asso-
ciated with a 5-fold increased risk of stroke, is an 
increasingly common disease. One of the estab-
lished AF treatment options is electrical cardiover-
sion, which is particularly used for highly 
symptomatic chronic or persistent AF. In electrical 
cardioversion, ECG-synchronised electric shocks 
are applied to the heart to correct its rhythm, by 
resetting the cardiac cell activation mechanism 
within the heart.
Shocks can be applied externally or internally, 
but in either case, hospitalisation is required. In 
transthoracic cardioversion, the electrodes are 
placed on the skin, delivering shocks across the 
chest cavity. This requires anaesthesia, owing to the 
pain caused by the 150-200 J shocks. Internal 
cardioversion is also painful, requiring sedation, 
but in this case, the electrodes are two defi brillation 
catheters, placed within the heart, delivering shocks 
of up to 20 J directly across the atrial chambers.
Modern surgically implanted cardioverter 
defi brillator (ICD) devices can also be confi gured 
for AF therapy, delivering their shocks between 
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Venezuela and Ohio State University in the US, 
have been working on controlled delivery of 
electrical cardioversion-level electrical energy to 
the heart muscle (myocardium), through the skin, 
without the use of wires.
In their paper in the current issue of Electronics 
Letters, the team report in-vivo testing of a por-
table, battery-less, implantable AF treatment defi -
brillator that also incorporates impedance 
measurement circuitry. Aimed at use in a clinical 
setting, their wirelessly-powered impedance com-
pensated passive implantable defi brillator (IC-
PIAD) device has been designed to provide a new 
option for AF treatment, as team member Prof. 
Omar Escalona explained: “The IC-PIAD technol-
ogy is a paradigmatically different concept from 
current ICDs; it provides a passive implantable 
AF-indicated device without an implanted battery 
or large capacitor, which is light and small, and 
offers an alternative for AF treatment without 
anxiety related discomfort; requiring only light 
sedation.”
Reading rhythms
The in situ impedance sensing allows  capture of 
the electrical impedance spectrum of the myocar-
dium prior to, and between, successive defi brilla-
tion attempts. This can potentially be used to allow 
optimisation of the applied shocks prior to delivery, 
thereby reducing the energy applied and so the 
discomfort of cardioversion. In-vivo testing indi-
cates that a fairly signifi cant reduction in the energy 
required for successful cardioversion should be 
possible through impedance compensation.
The team believe that further development of 
the IC-PIAD concept, to incorporate micro-shock 
sequencing combined with real-time ECG sensing 
and processing, may eliminate the need for seda-
tion entirely. This kind of treatment could then be 
brought into the home-healthcare sphere, if sup-
ported by reliable e-Health services.
In the immediate future, the team intend to use 
the IC-PIAD as an enabling technology to facilitate 
development of novel waveforms and algorithms for 
improved AF defi brillation. They expect that a fi rst 
version of the IC-PIAD could be available on the 
market, for use in patients, in about 5-6 years. Sub-
mission as a passive, non-automatic shock delivery, 
implantable device should shorten FDA approval 
time, due to the lack of an implanted battery. “All of 
the main elements of the design have already been 
separately or jointly tested in acute pre-clinical or 
clinical trials,” said Escalona. “As for the longer 
term, knowledge derived from this research has 
already led to European Development funding to 
develop a new concept in wireless energy supply for 
driving high-powered medical implants to address a 
world healthcare problem with advanced heart 
failure patients awaiting heart transplant.”
FURTHER READING
http://www.cacr.ulster.ac.uk/
http://www.nibec.ulster.ac.uk/
✪
Page 1192
‘Impedance 
compensated passive 
implantable atrial 
deﬁ brillator’, 
P. R. Walsh, 
P. A. Rodrigues, 
J. J. Velasquez, 
N. Waterman and 
O. J. Escalona
➔
Battery-free, wireless implantable deﬁ brillator for atrial ﬁ brilla-
tion could reduce pain and care requirements in electrical heart 
treatment
straight to the heart 
✪
